Aravive, Inc.
(NASDAQ : VSAR)

( )
VSAR After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.83%191.561.2%$567.63m
GILDGilead Sciences, Inc.
-0.97%70.490.9%$501.34m
BIIBBiogen Inc.
-1.94%318.901.3%$457.42m
CELGCelgene Corporation
-4.05%71.021.2%$422.10m
ILMNIllumina, Inc.
-5.73%310.393.5%$402.00m
REGNRegeneron Pharmaceuticals, Inc.
-2.83%346.562.6%$291.08m
VRTXVertex Pharmaceuticals Incorporated
-4.27%172.851.9%$281.35m
ALXNAlexion Pharmaceuticals, Inc.
-3.92%118.602.0%$203.65m
AAgilent Technologies, Inc.
-4.12%64.501.5%$169.81m
LGNDLigand Pharmaceuticals Incorporated
-1.97%155.4723.3%$152.44m
EXASExact Sciences Corporation
-8.54%68.2525.3%$149.11m
SRPTSarepta Therapeutics, Inc.
-3.70%120.8216.4%$136.29m
ECYTEndocyte, Inc.
-0.04%23.552.0%$123.58m
INCYIncyte Corporation
-4.80%62.862.5%$111.57m
BMRNBioMarin Pharmaceutical Inc.
-2.72%93.074.3%$110.69m

Company Profile

Aravive, Inc. is a clinical stage biotechnology company focused on developing innovative therapies that target treatment for cancer. Its product portfolio include AVB-S6-500 which is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on July 6, 2016 and is headquartered in Houston, TX.